Clinical Trials Logo

Filter by:
NCT ID: NCT01452776 Completed - Erosive Esophagitis Clinical Trials

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety of long term use of TAK-438, once daily (QD), for the maintenance treatment of healed erosive esophagitis.

NCT ID: NCT01452763 Completed - Gastric Ulcers Clinical Trials

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.

NCT ID: NCT01452750 Completed - Gastric Ulcers Clinical Trials

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).

NCT ID: NCT01452724 Completed - Duodenal Ulcer Clinical Trials

Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with duodenal ulcer.

NCT ID: NCT01452711 Completed - Gastric Ulcer Clinical Trials

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer

Start date: November 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with gastric ulcer.

NCT ID: NCT01452698 Completed - Erosive Esophagitis Clinical Trials

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.

NCT ID: NCT01452685 Completed - Endometriosis Clinical Trials

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the long term safety and efficacy of TAK-385, once daily (QD) following continued administration in participants who completed a Phase II dose-finding study.

NCT ID: NCT01452659 Completed - Uterine Fibroids Clinical Trials

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.

NCT ID: NCT01451203 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA) who are naive to MTX and have with poor prognostic factors, using inhibition of radiographically confirmed joint damage progression over a one-year period as a primary endpoint. Following a year of treatment with CZP plus MTX treatment, CZP will be discontinued, and the subjects will be monitored for one more year (the follow-up period) to investigate the sustainability of efficacy of CZP during the MTX monotherapy for exploratory purposes.

NCT ID: NCT01451164 Completed - Schizophrenia Clinical Trials

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Start date: October 2011
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.